<p>Serum CTRP3 Levels In Obese Children: A Potential Protective Adipokine Of Obesity, Insulin Sensitivity And Pancreatic β Cell Function</p>

Abstract

PurposeCTRP3 is a novel peptide that has recently emerged as an important regulatory adipokine of obesity and related metabolic disease. Little is known about its role in children. The current study aimed to investigate the potential role of CTRP3 in obese children and explore its relationships with insulin sensitivity, pancreatic β cell function, and obesity-related markers.Patients and methodsWe studied the levels of serum CTRP3 in 48 obese and 36 normal weight pre-puberty children. The levels of blood pressure, lipids, glucose, and insulin were measured, and the values of HOMA-IR, HOMA-β and insulinogenic index were calculated. The correlations of these measurements with CTRP3 levels were analyzed.ResultsIn this study, we found that CTRP3 serum levels significantly decreased in obese children compared to controls, and insulin resistant obese subjects have lower CTRP3 levels in contrast with the non-insulin resistant obese subjects. Moreover, serum CTRP3 concentrations significantly decreased, while glucose and insulin concentrations significantly increased after a 3 hrs oral glucose tolerance test in obese children. Furthermore, Serum CTRP3 levels correlated negatively and significantly with BMI, triglycerides, systolic blood pressure, fasting insulin, glucose, HOMA-IR, HOMA-β and insulinogenic index in obese children.ConclusionIn summary, serum CTRP3 levels significantly decreased in obese children, and negatively correlated with insulin resistance and pancreatic β cell function indicators. Therefore, CTRP3 may play a protective role in the glucose homeostasis and tightly related to β cell function as well as obesity-related markers in obese children.

Downregulation of CTRP-3 by Weight Loss In Vivo and by Bile Acids and Incretins in Adipocytes In Vitro

“…CTRP-3 concentrations were reduced to about 60% of baseline levels at study point V3 (three months after surgery or start of dietary intervention, respectively). Thus, systemic CTRP-3 appears to be down-regulated within the context of weight loss, a finding that was somewhat surprising due to the inverse relation of CTRP-3 levels and BMI known from the literature [13][14][15]. Reduction of body weight and BMI might have been expected to be accomplished by an increase of CTRP-3.…”

“…Therefore, CTRP-3 represents a putative regulatory element linking metabolism and inflammation ("metaflammation"). Similar to adiponectin, a negative correlation of systemic CTRP-3 levels with the occurrence of obesity and type 2 diabetes mellitus (T2D) has repeatedly been reported [13][14][15]. However, circulating levels were not affected in short term by an oral lipid load or during an oral glucose tolerance test in subjects from a cross-sectional study cohort [16].…”

“…Besides its immuno-modulating functions as a potent LPS-antagonist in adipocytes and adipose tissue inflammation [8,9,12], the beneficial effects of CTRP-3 on glucose and lipid metabolism have been characterized in recent years [6,11]. Most interestingly and similar to adiponectin, systemic CTRP-3 levels have repeatedly been described to be lower in subjects suffering from obesity and/or type 2 diabetes mellitus when compared to normal-weight and normo-glycemic individuals [13][14][15]. Despite these consistent findings and despite the high relevance of local and systemic CTRP-3 effects in the regulation of inflammatory and metabolic processes, there is a considerable lack of data in the literature regarding the effects of weight loss on circulating CTRP-3 levels in obesity.…”

Circulating Adipokine Levels in Nonobese Women With Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis

“…As adipokines are involved in many critical physiological processes in the body, dysregulation of adipokines may lead to endocrine diseases ( 5 ). Additionally, research has shown that adipokines play an essential role in the pathogenesis of obesity and obesity-related diseases ( 6 ).…”

Circulating adipokines in non-obese PCOS patients: a systematic review and meta-analysis

“…Therefore, abnormal changes in adipokines may also lead to some endocrine diseases in the body 5 . Besides, studies have shown that adipokines play an essential role in the pathogenesis of obesity and obesity-related diseases 6 .…”